Aurora Cannabis
Aurora Cannabis Inc. produces and distributes medical cannabis products. The last earnings update was 11 days ago. More info.
Add to Portfolio Compare Print
- Aurora Cannabis has significant price volatility in the past 3 months.
ACB Share Price and Events
7 Day Returns
1 Year Returns
ACB Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Aurora Cannabis (ACB) | 0% | 12.6% | 16.3% | -12% | 1424.6% | - |
| CA Pharmaceuticals | -0.6% | 9.5% | 19.7% | -8.1% | 887.4% | -30.3% |
| CA Market | 2.2% | 4.5% | 5.4% | 0.5% | 24% | 6.1% |
1 Year Return vs Industry and Market
- ACB underperformed the Pharmaceuticals industry which returned -8.1% over the past year.
- ACB underperformed the Market in Canada which returned 0.5% over the past year.
Price Volatility
Related Companies
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Aurora Cannabis
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Aurora Cannabis.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 6 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 18.1% |
| Perpetual Growth Rate | 10-Year CA Government Bond Rate | 1.9% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year CA Govt Bond Rate | 1.9% |
| Equity Risk Premium | S&P Global | 8.1% |
| Pharmaceuticals Unlevered Beta | Simply Wall St/ S&P Global | 3.16 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 3.157 (1 + (1- 26.5%) (3.74%)) |
3.243 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
2 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (2 * 8.05%) |
18.05% |
Discounted Cash Flow Calculation for TSX:ACB using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Aurora Cannabis is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (CAD, Millions) | -370.08 | 76.53 | 337.67 | 586.86 | 458.55 |
| Source | Analyst x4 | Analyst x2 | Analyst x2 | Analyst x2 | Analyst x1 |
|
Present Value Discounted (@ 18.05%) |
-313.49 | 54.92 | 205.24 | 302.15 | 199.99 |
| Present value of next 5 years cash flows | CA$448.81 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= CA$458.55 × (1 + 1.95%) ÷ (18.05% – 1.95%) |
CA$2,902.51 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= CA$2,902.51 ÷ (1 + 18.05%)5 |
CA$1,265.87 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= CA$448.81 + CA$1,265.87 |
CA$1,714.67 |
| Equity Value per Share (CAD) |
= Total value / Shares Outstanding
= CA$1,714.67 / 998.60 |
CA$1.72 |
| Calculation | Result | |
|---|---|---|
| Value per share (CAD) | From above. | CA$1.72 |
| Current discount | Discount to share price of
CA$9.30
= -1 x (CA$9.30 - CA$1.72) / CA$1.72 |
-441.6% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
- The current share price of Aurora Cannabis is above its future cash flow value.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Aurora Cannabis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Aurora Cannabis's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in CAD | CA$-0.10 |
| TSX:ACB Share Price ** | TSX (2019-02-21) in CAD | CA$9.3 |
| Canada Pharmaceuticals Industry PE Ratio | Median Figure of 15 Publicly-Listed Pharmaceuticals Companies | 21.51x |
| Canada Market PE Ratio | Median Figure of 552 Publicly-Listed Companies | 14.82x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Aurora Cannabis.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = TSX:ACB Share Price ÷ EPS (both in CAD) = 9.3 ÷ -0.10 |
-93.58x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aurora Cannabis is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
- Aurora Cannabis is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does
Aurora Cannabis's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -93.58x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts |
113.4%per year |
| Canada Pharmaceuticals Industry PEG Ratio | Median Figure of 10 Publicly-Listed Pharmaceuticals Companies | 0.9x |
| Canada Market PEG Ratio | Median Figure of 257 Publicly-Listed Companies | 0.94x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Aurora Cannabis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Aurora Cannabis's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in CAD | CA$4.30 |
| TSX:ACB Share Price * | TSX (2019-02-21) in CAD | CA$9.3 |
| Canada Pharmaceuticals Industry PB Ratio | Median Figure of 120 Publicly-Listed Pharmaceuticals Companies | 3.25x |
| Canada Market PB Ratio | Median Figure of 2,330 Publicly-Listed Companies | 1.55x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = TSX:ACB Share Price ÷ Book Value per Share (both in CAD) = 9.3 ÷ 4.30 |
2.16x |
* Primary Listing of Aurora Cannabis.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Aurora Cannabis is good value based on assets compared to the CA Pharmaceuticals industry average.
Value checks
We assess Aurora Cannabis's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) Aurora Cannabis has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Aurora Cannabis's earnings growth is expected to exceed the low risk savings rate of 1.9%.
Growth vs Market Checks
- Aurora Cannabis's earnings growth is expected to exceed the Canada market average.
- Aurora Cannabis's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| TSX:ACB Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts | 113.4% |
| TSX:ACB Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts | 46.5% |
| Canada Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 85.8% |
| Canada Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 49.2% |
| Canada Market Earnings Growth Rate | Market Cap Weighted Average | 18% |
| Canada Market Revenue Growth Rate | Market Cap Weighted Average | 6.9% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 2,700 | 2 | ||
| 2022-06-30 | 2,220 | 936 | 2 | |
| 2021-06-30 | 1,522 | 567 | 162 | 4 |
| 2020-06-30 | 907 | 204 | -12 | 6 |
| 2019-06-30 | 316 | -298 | -221 | 5 |
| Date (Data in CAD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 119 | -206 | -72 |
| 2018-09-30 | 77 | -146 | 174 |
| 2018-06-30 | 55 | -82 | 72 |
| 2018-03-31 | 42 | -34 | -13 |
| 2017-12-31 | 31 | -16 | 7 |
| 2017-09-30 | 23 | -15 | -4 |
| 2017-06-30 | 18 | -13 | -13 |
| 2017-03-31 | 13 | -17 | -16 |
| 2016-12-31 | 8 | -11 | -13 |
| 2016-09-30 | 5 | -9 | -10 |
| 2016-06-30 | 1 | -7 | -6 |
| 2016-03-31 | 0 | -5 | -0 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (1 month ago) | See Below |
| Future Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
All data from Aurora Cannabis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-06-30 | 0.73 | 0.73 | 0.73 | 1.00 |
| 2022-06-30 | 0.52 | 0.52 | 0.52 | 1.00 |
| 2021-06-30 | 0.29 | 0.29 | 0.29 | 1.00 |
| 2020-06-30 | -0.01 | 0.06 | -0.08 | 2.00 |
| 2019-06-30 | -0.24 | -0.20 | -0.26 | 3.00 |
| Date (Data in CAD Millions) | EPS * |
|---|---|
| 2018-12-31 | -0.10 |
| 2018-09-30 | 0.30 |
| 2018-06-30 | 0.16 |
| 2018-03-31 | -0.03 |
| 2017-12-31 | 0.02 |
| 2017-09-30 | -0.01 |
| 2017-06-30 | -0.05 |
| 2017-03-31 | -0.07 |
| 2016-12-31 | -0.07 |
| 2016-09-30 | -0.07 |
| 2016-06-30 | -0.04 |
| 2016-03-31 | -0.00 |
*GAAP earnings excluding extraordinary items.
Future performance checks
We assess Aurora Cannabis's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Aurora Cannabis has a total score of 6/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Aurora Cannabis performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Aurora Cannabis does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare Aurora Cannabis's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Aurora Cannabis's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from Aurora Cannabis Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in CAD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 119.10 | -71.64 | 252.51 | 6.64 |
| 2018-09-30 | 76.62 | 173.84 | 187.11 | 5.00 |
| 2018-06-30 | 55.20 | 71.94 | 109.86 | 1.68 |
| 2018-03-31 | 41.99 | -12.75 | 68.43 | 0.88 |
| 2017-12-31 | 31.06 | 6.61 | 44.51 | 0.45 |
| 2017-09-30 | 23.25 | -3.80 | 30.82 | 0.38 |
| 2017-06-30 | 18.07 | -12.97 | 24.67 | 0.31 |
| 2017-03-31 | 13.35 | -15.63 | 18.96 | 0.44 |
| 2016-12-31 | 8.40 | -13.24 | 12.87 | 0.50 |
| 2016-09-30 | 4.51 | -9.97 | 7.71 | 0.51 |
| 2016-06-30 | 1.44 | -5.72 | 5.63 | 0.57 |
| 2016-03-31 | 0.22 | -0.01 | 4.95 | 0.52 |
| 2015-12-31 | -3.31 | 4.40 | 0.53 | |
| 2015-09-30 | -10.16 | 3.65 | 0.50 | |
| 2015-06-30 | -9.52 | 3.63 | 0.43 | |
| 2014-06-30 | -2.19 | 0.60 | 0.31 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Aurora Cannabis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Aurora Cannabis has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Aurora Cannabis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Aurora Cannabis's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Aurora Cannabis has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Aurora Cannabis's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Aurora Cannabis's finances.
The net worth of a company is the difference between its assets and liabilities.
- Aurora Cannabis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Aurora Cannabis's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Aurora Cannabis Company Filings, last reported 1 month ago.
| Date (Data in CAD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | 4,300.05 | 347.56 | 164.80 |
| 2018-09-30 | 4,402.92 | 291.10 | 494.04 |
| 2018-06-30 | 1,563.13 | 203.21 | 148.38 |
| 2018-03-31 | 1,386.77 | 209.26 | 288.43 |
| 2017-12-31 | 555.59 | 0.32 | 427.75 |
| 2017-09-30 | 244.92 | 66.92 | 162.68 |
| 2017-06-30 | 218.93 | 63.89 | 174.56 |
| 2017-03-31 | 161.62 | 18.79 | 112.99 |
| 2016-12-31 | 74.82 | 20.62 | 55.85 |
| 2016-09-30 | 41.10 | 13.53 | 23.19 |
| 2016-06-30 | 5.96 | 10.49 | 0.24 |
| 2016-03-31 | 11.48 | 9.89 | 0.86 |
| 2015-12-31 | 5.78 | 9.39 | 0.54 |
| 2015-09-30 | 3.07 | 9.31 | 0.69 |
| 2015-06-30 | 3.83 | 8.37 | 0.32 |
| 2014-06-30 | 1.77 | 1.85 | 0.92 |
- Aurora Cannabis's level of debt (8.1%) compared to net worth is satisfactory (less than 40%).
- Unable to establish if Aurora Cannabis's debt level has increased without past 5-year debt data.
- Operating cash flow is negative therefore debt is not well covered.
- Aurora Cannabis is making a loss, therefore interest payments are not well covered by earnings.
Financial health checks
We assess Aurora Cannabis's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Aurora Cannabis has a total score of 2/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Aurora Cannabis's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
CA$2,000 of
Aurora Cannabis
shares you are expected to receive
CA$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Aurora Cannabis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Aurora Cannabis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 6 Analyst Estimates (S&P Global) | See Below |
| North America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 2.7% |
| Canada Market Average Dividend Yield | Market Cap Weighted Average of 331 Stocks | 3.5% |
| Canada Minimum Threshold Dividend Yield | 10th Percentile | 1.1% |
| Canada Bottom 25% Dividend Yield | 25th Percentile | 2.1% |
| Canada Top 25% Dividend Yield | 75th Percentile | 5.8% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in CA$) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-06-30 | ||
| 2022-06-30 | ||
| 2021-06-30 | ||
| 2020-06-30 | ||
| 2019-06-30 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Aurora Cannabis has not reported any payouts.
- Unable to verify if Aurora Cannabis's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Aurora Cannabis's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Aurora Cannabis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Aurora Cannabis has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | CA$1,595,172 |
| AGE | 53 |
| TENURE AS CEO | 4.2 years |
CEO Bio
Mr. Terry Booth founded Aurora Cannabis Inc. in 2013 and has been its Chief Executive Officer since December 9, 2014. Mr. Booth oversees Aurora's corporate strategy including operations, sales, patient acquisition, genetics development, regulatory affairs, facility expansion as well as communicating with capital markets and investors. He has assembled a diverse and highly skilled team of experts from a broad range of disciplines to execute on the Radient Technologies well-differentiated business strategy and vision to build the world's foremost cannabis company. An entrepreneur and Alberta business leader, Mr. Booth, who at 22 was Alberta's youngest ever master electrician, has serves as President and served as Chief Executive Officer of six other highly successful businesses, one of which, Superior Safety Codes Inc. He served as Non-Independent Non-Executive Director of Radient Technologies Inc. since November 30, 2017 until February 4, 2019. Mr. Booth has been a Director of Aurora Cannabis Inc. since December 9, 2014. He has been a Director of Liquor Stores N.A. Ltd. since March 14, 2018. Mr. Booth has been Director at Quinsam Capital Corporation since August 30, 2017. He has received an award as one of Canada's top 50 fastest-growing companies.
CEO Compensation
- Terry's compensation has been consistent with company performance over the past year.
- Terry's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure
Average tenure and age of the Aurora Cannabis management team in years:
- The average tenure for the Aurora Cannabis management team is less than 2 years, this suggests a new team.
Management Team
Terry Booth
Founder
CA$2M
53
4.2 yrs
Steve Dobler
Founder
CA$1M
53
4.2 yrs
Glen Ibbott
Chief Financial Officer
CA$1M
1.8 yrs
Allan Cleiren
Chief Operating Officer
CA$1M
1.8 yrs
Cam Battley
Chief Corporate Officer
CA$1M
2.3 yrs
Jose del Moral
CA$511K
39
0.9 yrs
Darryl Vleeming
Chief Information Officer
1.3 yrs
Jonathan Page
Chief Science Officer
0.3 yrs
Marc Lakmaaker
VP of Investor Relations & Corporate Development
Jillian Swainson
Senior VP & General Counsel
1.1 yrs
Board of Directors Tenure
Average tenure and age of the Aurora Cannabis board of directors in years:
- The average tenure for the Aurora Cannabis board of directors is less than 3 years, this suggests a new board.
Board of Directors
Michael Singer
Chairman
CA$1M
53
2.3 yrs
Terry Booth
Founder
CA$2M
53
4.2 yrs
Steve Dobler
Founder
CA$1M
53
4.2 yrs
Jason Ronald Dyck
Director
CA$2M
3.9 yrs
Adam Szweras
Director
CA$849K
46
3.5 yrs
Diane Jang
Director
CA$206K
1.3 yrs
Norma Beauchamp
Independent Director
0.6 yrs
Ronald Funk
Independent Director
62
0.6 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (CA$) | Value (CA$) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 28. Dec 18 | Sell | Terry Booth | Individual | 13. Mar 18 | 13. Mar 18 | -464,183 | CA$11.54 | CA$-5,358,064 | ||
| 06. Oct 18 | Sell | Michael Singer | Individual | 03. Oct 18 | 04. Oct 18 | -115,428 | CA$12.16 | CA$-1,169,525 | ||
| 02. Oct 18 | Sell | Diane Jang | Individual | 28. Sep 18 | 28. Sep 18 | -14,134 | CA$12.32 | CA$-173,735 | ||
| 17. Aug 18 | Buy | Allan Cleiren | Individual | 17. Aug 18 | 17. Aug 18 | 39,600 | CA$6.36 | CA$251,828 | ||
| 27. Jul 18 | Sell | Stephen Dobler | Individual | 24. Jul 18 | 24. Jul 18 | -1,386,100 | CA$7.70 | CA$-10,672,970 | ||
| 15. May 18 | Sell | Jason Ronald Dyck | Individual | 29. Dec 17 | 29. Dec 17 | -379,215 | CA$9.99 | CA$-3,788,358 | ||
| 04. May 18 | Sell | Adam Szweras | Individual | 12. Mar 18 | 12. Mar 18 | -200,000 | CA$11.42 | CA$-2,283,840 | ||
| 10. Apr 18 | Buy | Jason Ronald Dyck | Individual | 09. Apr 18 | 09. Apr 18 | 25,500 | CA$7.80 | CA$198,900 | ||
| 07. Apr 18 | Buy | Glen Ibbott | Individual | 02. Apr 18 | 02. Apr 18 | 20,000 | CA$8.78 | CA$175,600 | ||
| 29. Mar 18 | Buy | Ronan Levy | Individual | 28. Mar 18 | 28. Mar 18 | 27,000 | CA$9.19 | CA$248,130 | ||
| 29. Mar 18 | Buy | Cameron Battley | Individual | 28. Mar 18 | 28. Mar 18 | 27,685 | CA$9.04 | CA$250,217 | ||
| 19. Mar 18 | Sell | Dale Lesack | Individual | 12. Mar 18 | 16. Mar 18 | -105,000 | CA$11.88 | CA$-1,223,950 | ||
| 16. Mar 18 | Sell | Ronan Levy | Individual | 13. Mar 18 | 13. Mar 18 | -50,000 | CA$11.56 | CA$-578,000 | ||
| 16. Mar 18 | Sell | Neil Belot | Individual | 12. Mar 18 | 13. Mar 18 | -242,000 | CA$11.51 | CA$-2,776,166 | ||
| 16. Mar 18 | Sell | Stephen Dobler | Individual | 13. Mar 18 | 13. Mar 18 | -900,000 | CA$11.54 | CA$-10,388,700 | ||
| 03. Mar 18 | Buy | Debra Wilson | Individual | 28. Feb 18 | 28. Feb 18 | 35 | CA$10.64 | CA$372 | ||
| 23. Feb 18 | Sell | Nilda Rivera | Individual | 21. Feb 18 | 21. Feb 18 | -200,000 | CA$10.94 | CA$-2,188,000 | ||
Management checks
We assess Aurora Cannabis's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Aurora Cannabis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Has Aurora Cannabis Inc (TSE:ACB) Got Enough Cash?
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Aurora Cannabis Inc (TSE:ACB), with a market capitalization of CA$9.0b, rarely draw their attention from the investing community. … Let’s take a look at ACB’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures. … How does ACB’s operating cash flow stack up against its debt?
Simply Wall St - – Full articleWhy Aurora Cannabis Inc's (TSE:ACB) ROE Of 4.4% Does Not Tell The Whole Story
Over the last twelve months Aurora Cannabis has recorded a ROE of 4.4%. … View our latest analysis for Aurora Cannabis? … Return on Equity = Net Profit ÷ Shareholders' Equity
Simply Wall St - – Full articleWhen Will Aurora Cannabis Inc (TSE:ACB) Become Profitable?
Aurora Cannabis Inc's (TSE:ACB):. … Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada. … With the latest financial year loss of -CA$12.97m and a trailing-twelve month of -CA$12.75m, the CA$5.39b market-cap alleviates its loss by moving closer towards its target of breakeven.
Simply Wall St - – Full articleAurora Cannabis Inc's (TSE:ACB) Shift From Loss To Profit
In this article, I will touch on the expectations for ACB’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 152.84% year-on-year, on average, which is rather optimistic! … TSX:ACB Past Future Earnings May 15th 18 Underlying developments driving ACB’s growth isn’t the focus of this broad overview, but, bear in mind that generally a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in.
Simply Wall St - – Full articleWhat’s Ahead For Aurora Cannabis Inc (TSE:ACB)?
TSX:ACB PE PEG Gauge May 8th 18 The pharmaceutical industry is trading at a PE ratio of 46.75x, higher than the rest of the Canadian stock market PE of 15.64x. … On the stock-level, Aurora Cannabis is trading at a higher PE ratio of 446x, making it more expensive than the average pharmaceutical stock. … If Aurora Cannabis has been on your watchlist for a while, now may not be the best time to enter into the stock since it is trading at a higher valuation compared to other pharmaceutical companies.
Simply Wall St - – Full articleIs Aurora Cannabis Inc (TSE:ACB) A Financially Strong Company?
This article will examine ACB’s financial liquidity and debt levels to get an idea of whether the company can deal with cyclical downturns and maintain funds to accommodate strategic spending for future growth. … View our latest analysis for Aurora Cannabis How does ACB’s operating cash flow stack up against its debt? … Next Steps: Although ACB’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.
Simply Wall St - – Full articleWill Aurora Cannabis Inc (TSE:ACB) Continue To Underperform Its Industry?
Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Aurora Cannabis’s equity capital deployed. … Since Aurora Cannabis’s return does not cover its cost, with a difference of -16.78%, this means its current use of equity is not efficient and not sustainable. … Currently Aurora Cannabis has virtually no debt, which means its returns are predominantly driven by equity capital.
Simply Wall St - – Full articleIs Aurora Cannabis Inc's (TSE:ACB) CEO Salary Justified?
View our latest analysis for Aurora Cannabis What has been the trend in ACB's earnings? … Performance can be measured based on factors such as earnings and total shareholder return (TSR). … Normally I would use earnings and market cap to account for variations in performance, however, ACB's negative earnings lower the usefulness of my formula.
Simply Wall St - – Full articleAre Aurora Cannabis Inc's (TSE:ACB) Interest Costs Too High?
To assess this, I compare ACB's cash and other liquid assets against its upcoming debt. … Our analysis shows that ACB is able to meet its upcoming commitments with its cash and other short-term assets, which lessens our concerns for the company's business operations should any unfavourable circumstances arise. … Although ACB’s debt level is relatively low, its cash flow levels still could not copiously cover its borrowings.
Simply Wall St - – Full articleHas Aurora Cannabis Inc (TSX:ACB) Improved Earnings Growth In Recent Times?
In this article, I will take a look at Aurora Cannabis Inc's (TSX:ACB) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … TSX:ACB Income Statement Dec 4th 17 We can further analyze Aurora Cannabis's loss by looking at what has been happening in the industry as well as within the company. … Aurora Cannabis's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story.
Simply Wall St - – Full articleCompany Info
Map
Description
Aurora Cannabis Inc. produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution. The company’s products consist of dried cannabis and cannabis oil; CanniMed vegan capsules; and hemp products, as well as sells vaporizers, consumable vaporizer accessories, and herb mills for using herbal cannabis products. It also operates CanvasRX, a network of cannabis counseling and outreach centers; and provides cannabis analytical product testing services. The company has operations in 19 countries across five continents. Aurora Cannabis Inc. has collaboration agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart for the distribution, sale, and marketing of medical cannabis products through their respective networks of pharmacies. The company has a strategic agreements with Hempco Food and Fiber Inc.; CTT Pharmaceuticals Inc.; Choom Holdings Inc.; Capcium Inc.; The Green Organic Dutchman Holdings Ltd.; Société des Alcools du Québec; Alcanna; Radient Technologies; Micron Waste; Wagner Dimas; Evio; and Cann Group Limited. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Details
| Name: | Aurora Cannabis Inc. |
| ACB | |
| Exchange: | TSX |
| Founded: | |
| CA$9,286,943,013 | |
| 998,596,023 | |
| Website: | http://auroramj.com |
| Address: |
Aurora Cannabis Inc. 10355 Jasper Avenue, Suite 500, Edmonton, Alberta, T5J 1Y6, Canada |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| TSX | ACB | Common Shares | The Toronto Stock Exchange | CA | CAD | 18. Dec 2014 | |
| NYSE | ACB | Common Shares | New York Stock Exchange | US | USD | 18. Dec 2014 | |
| DB | 21P | Common Shares | Deutsche Boerse AG | DE | EUR | 18. Dec 2014 | |
| LSE | 0UJG | Common Shares | London Stock Exchange | GB | CAD | 18. Dec 2014 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/22 01:04 |
| End of day share price update: | 2019/02/21 00:00 |
| Last estimates confirmation: | 2019/02/21 |
| Last earnings filing: | 2019/02/11 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/06/30 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
